Clinical trial NCT00486759: A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Comparing the Efficacy of Bevacizumab in Combination With Rituximab and CHOP (R-CHOP + Bevacizumab) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: B-cell Lymphoma
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
Collaborators: name: Genentech, Inc.
First posted: 2007-06-15
Enrollment: 787
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This 2-arm study was designed to compare the efficacy and safety of bevacizumab (Avastin) in combination with rituximab (MabThera) and CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone) chemotherapy (R-CHOP) versus rituximab plus CHOP chemotherapy (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL). Patients were randomized to receive 8 cycles of treatment with R-CHOP plus bevacizumab or R-CHOP plus placebo. Treatment with bevacizumab/placebo and R-CHOP was given either on a 2-week or 3-week schedule and bevacizumab was given at a weekly average dose of 5 mg/kg (10 mg/kg for 2-week cycles and 15 mg/kg for 3-week cycles).

Detailed description: An independent Data and Safety Monitoring Board (DSMB) was established to review safety data collected during the study on an ongoing basis. At its meeting in December 2009, the DSMB noted a trend for increased cardiac toxicity in the experimental arm (R-CHOP + bevacizumab) compared with the control arm (R-CHOP + placebo). Additional efficacy analyses of data from 720 randomized patients were presented at a DSMB meeting on May 22, 2010; they indicated no improvement in efficacy with the addition of bevacizumab to R-CHOP. It was noted, however, that there was an apparent increase in the risk of cardiotoxicity, premature treatment withdrawal, serious adverse events (SAEs), fatal adverse events (AEs), and perforation/ulcer in the experimental arm. Based on its assessment of an increased risk with unlikely benefit for patients randomized to the experimental arm, the DSMB recommended that further enrollment in the study be permanently halted and that bevacizumab be discontinued for any patients randomized to the experimental arm. On May 31, 2010, the sponsor took the decision to stop enrollment into the study and the bevacizumab treatment was terminated with immediate effect as recommended by the DSMB.

The study protocol was amended. The primary objective of the study was changed from evaluation of efficacy to evaluation of safety and the study was extended to include an 18-month safety follow-up period. Because enrollment was terminated prematurely resulting in fewer enrolled patients than planned, the outcome measure data are premature due to fewer than expected events.

The time frame for the reporting of serious adverse events was modified. Serious adverse events (SAE) unrelated to study treatment were reported until 1 year post-treatment or until new anti-lymphoma treatment was initiated. SAEs judged to be related to study treatment and congestive heart failure events were reported at any time during the study.

Eligibility criteria: Inclusion Criteria:

* Adult patients, ≥ 18 and \< 80 years of age.
* CD20-positive diffuse large B-cell lymphoma.
* Low-intermediate, high-intermediate, or high risk disease and/or bulky tumor (largest diameter ≥ 7.5 cm).
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

Exclusion Criteria:

* Prior treatment for diffuse large B-cell lymphoma.
* Types of non-Hodgkin's lymphoma other than diffuse large B-cell lymphoma (DLBCL).
* Central nervous system (CNS) involvement of lymphoma.

Primary outcomes:
measure: Progression-free Survival (PFS)
timeFrame: Baseline to end of the study (up to 4 years, 4 months)
Secondary outcomes:
measure: Overall Survival
timeFrame: Baseline to end of the study (up to 4 years, 4 months)
measure: Overall Response (OR) Assessed According to the Revised Response Criteria for Malignant Lymphoma
timeFrame: At the end of treatment (Cycle 8, up to 12 months)
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Uni of California - San Diego; Cancer Center & Dept of Medicine
state: California
city: Whittier
country: United States
facility: Kenmar Research Inst.
state: California
city: Aurora
country: United States
facility: University of Colorado Cancer Center Department of Hematology
state: Colorado
city: Jacksonville
country: United States
facility: Uni Medical Center; Division Of Hemotology/Oncology
state: Florida
city: West Palm Beach
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Marietta
country: United States
facility: Northwest Georgia Oncology Centers
state: Georgia
city: Kansas City
country: United States
facility: University of Kansas Medical Center; Department of Hematology
state: Kansas
city: Ann Arbor
country: United States
facility: St. Joseph Mercy Hospital; Department of Oncology
state: Michigan
city: Concord
country: United States
facility: Northeast Oncology Associates
state: North Carolina
city: Winston-Salem
country: United States
facility: Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates
state: North Carolina
city: Portland
country: United States
facility: Providence Portland Medical Center
state: Oregon
city: Charleston
country: United States
facility: Charleston Cancer Center
state: South Carolina
city: Dallas
country: United States
facility: Uni of Texas Southwestern Medical Center
state: Texas
city: San Antonio
country: United States
facility: Cancer Therapy & Research Center
state: Texas
city: Federal Way
country: United States
facility: Northwest Medical Specialties B
state: Washington
city: Puyallup
country: United States
facility: Rainier Physicians
state: Washington
city: Tacoma
country: United States
facility: Northwest Medical Specialties
state: Washington
city: Buenos Aires
country: Argentina
facility: Hospital Italiano; Haemathology
city: Buenos Aires
country: Argentina
facility: Fundaleu; Haematology
city: Buenos Aires
country: Argentina
facility: Hospital Britanico; Haematology
city: Córdoba
country: Argentina
facility: HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología
city: Greenslopes
country: Australia
facility: Greenslopes Private Hospital; Gallipoli Research Centre
state: Queensland
city: Woolloongabba
country: Australia
facility: Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology
state: Queensland
city: Adelaide
country: Australia
facility: Royal Adelaide Hospital; Haematology, Institute of Medical Veterinary Science
state: South Australia
city: Kurralta Park
country: Australia
facility: Ashford Cancer Center Research
state: South Australia
city: Frankston
country: Australia
facility: Frankston Hospital; Oncology/Haematology
state: Victoria
city: Melbourne
country: Australia
facility: Peter Maccallum Cancer Institute; Medical Oncology
state: Victoria
city: Melbourne
country: Australia
facility: Alfred Hospital; Bone Marrow Transplant Unit
state: Victoria
city: Wodonga
country: Australia
facility: Border Medical Oncology; Murray Valley Private Hospital
state: Victoria
city: Fremantle
country: Australia
facility: Fremantle Hospital; Haematology
state: Western Australia
city: Graz
country: Austria
facility: Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I
city: Salzburg
country: Austria
facility: Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
city: Wien
country: Austria
facility: Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
city: Goiania
country: Brazil
facility: Centro Goiano de Oncologia - CGO
state: GO
city: Ijui
country: Brazil
facility: Hospital de Caridade de Ijui; Oncologia
state: RS
city: Porto Alegre
country: Brazil
facility: Hospital das Clinicas - UFRGS; Hematologia
state: RS
city: Porto Alegre
country: Brazil
facility: Hospital Nossa Senhora da Conceicao
state: RS
city: Campinas
country: Brazil
facility: Hospital das Clinicas - UNICAMP
state: SP
city: Santo Andre
country: Brazil
facility: Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia
state: SP
city: Sao Paulo
country: Brazil
facility: Santa Casa de Misericordia de Sao Paulo; Hematologia e Hemoterapia
state: SP
city: Sao Paulo
country: Brazil
facility: Hospital das Clinicas - FMUSP; Hematologia
state: SP
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre; Dept of Medicine
state: Alberta
city: Edmonton
country: Canada
facility: Cross Cancer Institute ; Dept of Medical Oncology
state: Alberta
city: Winnipeg
country: Canada
facility: Cancer Care Manitoba
state: Manitoba
city: Moncton
country: Canada
facility: Moncton Hospital
state: New Brunswick
city: St. John's
country: Canada
facility: Health Science Centre
state: Newfoundland and Labrador
city: Halifax
country: Canada
facility: QEII HSC; Oncology
state: Nova Scotia
city: Kingston
country: Canada
facility: Cancer Centre of Southeastern Ontario; Kingston General Hospital
state: Ontario
city: Mississauga
country: Canada
facility: Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre
state: Ontario
city: Toronto
country: Canada
facility: Toronto Sunnybrook Regional Cancer Centre
state: Ontario
city: Toronto
country: Canada
facility: University Health Network; Princess Margaret Hospital; Medical Oncology Dept
state: Ontario
city: Windsor
country: Canada
facility: Windsor Regional Cancer Centre
state: Ontario
city: Greenfield Park
country: Canada
facility: Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie
state: Quebec
city: Montreal
country: Canada
facility: Mcgill University - Royal Victoria Hospital; Oncology
state: Quebec
city: Montreal
country: Canada
facility: McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
state: Quebec
city: Quebec City
country: Canada
facility: Hopital de L'Enfant-Jesus; Hematology
state: Quebec
city: Quebec City
country: Canada
facility: Chuq - Hopital Hotel Dieu de Quebec; Oncology
state: Quebec
city: Regina
country: Canada
facility: Allan Blair Cancer Centre
state: Saskatchewan
city: Saskatoon
country: Canada
facility: Saskatoon Cancer Centre; Uni of Saskatoon Campus
state: Saskatchewan
city: Beijing
country: China
facility: Cancer Hospital Chinese Academy of Medical Sciences.
city: Beijing
country: China
facility: Beijing Cancer Hospital
city: Beijing
country: China
facility: Beijing Union Hospital
city: Beijing
country: China
facility: General Hospital of Chinese PLA; Department of Hematology
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
city: Shanghai
country: China
facility: Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
city: Shanghai
country: China
facility: Changhai Hospital of Shanghai
city: Suzhou
country: China
facility: The Second Affiliated Hospital of Soochow University
city: Suzhou
country: China
facility: First Affiliated Hospital of Soochow University
city: Tianjin
country: China
facility: Tianjin Institute of Hematology & Blood Diseases Hospital
city: Xi'an
country: China
facility: The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital)
city: Bogota
country: Colombia
facility: Organizacion Sanitas Internacional
city: Medellin-Antioquia
country: Colombia
facility: Hospital Pablo Tobon Uribe
city: Medellin
country: Colombia
facility: Instituto Cancerologia Medellin; Clinica Las Americas
city: Pereira
country: Colombia
facility: Oncólogos de Occidente
city: Brno
country: Czechia
facility: Fakultni nemocnice Brno; Interni hematoonkologicka klinika
city: Hradec Kralove
country: Czechia
facility: Fn Hr. Kralove; IV. Interni Hematologicka Klinika
city: Olomouc
country: Czechia
facility: Fakultni nemocnice Olomouc; Hemato-onkologicka klinika
city: Plzen - Lochotin
country: Czechia
facility: Fakultni Nemocnice Plzen, Hematologicko-Onkologicke Oddeleni
city: Praha 2
country: Czechia
facility: VshEOBECNÁ FAKULTNÍ NEMOCNICE; I. INTERNI KLINIKA
city: Praha
country: Czechia
facility: Fakultní Nemocnice Královské Vinohrady; Hematologická Klinika
city: Guayaquil
country: Ecuador
facility: Teodoro Maldonado Carbo Hospital; Oncology Service
city: Quito
country: Ecuador
facility: Hospital Carlos Andrade Marin; Servicio de Oncología
city: Quito
country: Ecuador
facility: Hospital Solca Quito; Oncologia
city: Albi
country: France
facility: Clinique Claude Bernard; Onco Hematologie
city: Angers
country: France
facility: Centre Hospitalier Uni Ire; Service de Medecine D
city: Bordeaux
country: France
facility: Institut Bergonie; Hematologie Oncologie
city: Bordeaux
country: France
facility: Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie
city: Caen
country: France
facility: Centre Francois Baclesse; Comite 2
city: Clermont Ferrand
country: France
facility: Chu Estaing; Cons Hemato Medecine Interne
city: Dijon
country: France
facility: Chu Site Du Bocage;Hematologie Clinique
city: La Roche Sur Yon
country: France
facility: CH Dptal Les Oudairies; Hematologie Oncologie
city: La Tronche
country: France
facility: Hopital Albert Michallon; Oncologie
city: Le Mans
country: France
facility: Clinique Victor Hugo; Chimiotherapie
city: Lille
country: France
facility: Hopital Claude Huriez; Hematologie
city: Limoges
country: France
facility: Hopital Uni Ire Dupuytren; Hematologie
city: Lyon
country: France
facility: Centre Leon Berard; Departement Oncologie Medicale
city: Marseille
country: France
facility: Institut J Paolii Calmettes; Onco Hematologie 1
city: Montauban
country: France
facility: Clinique Pont de Chaume; Oncologie Et Radiotherapie
city: Montpellier
country: France
facility: Hopital Saint Eloi; Hematologie Oncologie Medicale
city: Nice
country: France
facility: Hopital de L'Archet; Hematologie Clinique
city: Nimes
country: France
facility: Polyclinique Kenval ; Radiotherapie Oncologie
city: Paris
country: France
facility: Institut Curie; Oncologie Medicale
city: Paris
country: France
facility: Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset)
city: Paris
country: France
facility: Hopital Pitie Salpetriere; Hematologie Clinique
city: Perpignan
country: France
facility: Hopital Saint Jean; Hematologie
city: Pessac
country: France
facility: Hopital De Haut Leveque; Hematologie Clinique
city: Pierre Benite
country: France
facility: Ch Lyon Sud; Hemato Secteur Jules Courmont
city: Poitiers
country: France
facility: Hopital De La Miletrie; Hematologie Et Oncologie Medicale
city: Rodez
country: France
facility: Ch Jacques Puel;Oncologie Medicale
city: Saint-Priest en Jarez
country: France
facility: ICL; Hematologie
city: Salouel
country: France
facility: Hopital Sud; Hematologie Clinique
city: Toulouse
country: France
facility: Hopital Purpan; Hematologie Clinique
city: Toulouse
country: France
facility: Clinique Pasteur; Oncologie Medicale
city: Tours
country: France
facility: Hopital Bretonneau; Hematologie Therapie Cellulaire
city: Vandoeuvre Les Nancy
country: France
facility: Hopitaux De Brabois; Hematologie Medecine Interne
city: Villejuif
country: France
facility: Institut Gustave Roussy; Unite D'Hematologie
city: Amberg
country: Germany
facility: Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie
city: Berlin
country: Germany
facility: Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
city: Berlin
country: Germany
facility: Charité; Onkologie & Hämatologie
city: Bremen
country: Germany
facility: DIAKO Ev. Diakonie-Krankenhaus Bremen GmbH; Med. Klinik II; Hämatologie und internistische Onkologie
city: Cottbus
country: Germany
facility: Carl-Thiem-Klinik Cottbus; Medizinische Klinik
city: Dortmund
country: Germany
facility: Klinikzentrum Mitte; Medizinische Klinik Gastroenterologie Haematologie / Onkologie
city: Dortmund
country: Germany
facility: St. Johannes Hospital; Abt. Innere Medizin
city: Eschweiler
country: Germany
facility: St Antonius Hospital; Haematologie/Onkologie
city: Frankfurt
country: Germany
facility: Krankenhaus Nordwest Medizinische Klinik
city: Fulda
country: Germany
facility: Klinik Fulda; Abt. Itz
city: Greifswald
country: Germany
facility: Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik
city: Göttingen
country: Germany
facility: Georg-August-Uniklinik ; Zentrum Innere Medizin Abt. Hämatologie & Onkologie
city: Hagen
country: Germany
facility: Kath.Krankenhaus Hagen gem.GmbH St.-Marien-Hospital
city: Hamburg
country: Germany
facility: Asklepios Klinik St. Georg; Allgemeine Innere Medizin
city: Hamburg
country: Germany
facility: Facharztzentrum Eppendorf, Studien GbR
city: Hamm
country: Germany
facility: Evang.Krankenhaus Abt. Hämatologie und Onkologie
city: Hamm
country: Germany
facility: St.-Marien-Hospital Klinik Knappenstraße; Klinik für Hämatologie und Onkologie
city: Hannover
country: Germany
facility: KRH Klinikum Siloah Medizinische Klinik III
city: Hildesheim
country: Germany
facility: St. Bernward-Krankenhaus
city: Homburg/Saar
country: Germany
facility: Universitaetsklinikum des Saarlandes; medizinische Klinik und Poliklinik; Innere Medizin I
city: Karlsruhe
country: Germany
facility: Städtisches Klinikum Karlsruhe gGmbH, II. Medizinische Klinik
city: Karlsruhe
country: Germany
facility: St. Vincentius Kliniken Ag; Medizinische Klinik Abt. 2
city: Landshut
country: Germany
facility: Tagesklinik Landshut; Hämatologie/Onkologie
city: Leipzig
country: Germany
facility: Universitätsklinikum Leipzig Medizinische Klinik II Gastroenterolog. u. Hepatolog.
city: Leipzig
country: Germany
facility: Klinikum St.Georg gGmbH Klinik für Internistische Onkologie und Hämotologie
city: Ludwigshafen
country: Germany
facility: Klinikum der Stadt Ludwigshafen; Medizinische Klinik A
city: Lübeck
country: Germany
facility: Universitätsklinikum Schleswig-Holstein / Campus Lübeck, Med. Klinik I, Hämatologie/Onkologie
city: Lüdenscheid
country: Germany
facility: Märkische Kliniken GmbH, Klinikum Lüdenscheid; Hämatologie / Onkologie
city: Magdeburg
country: Germany
facility: Otto von Guericke Uni Magdeburg Uniklinik; Hämatologie/Onkologie
city: Magdeburg
country: Germany
facility: Klinikum Magdeburg gemeinnützige GmbH; Klinik Haematologie und Onkologie
city: Mannheim
country: Germany
facility: Klinikum Mannheim III. Medizinische Klinik
city: Muenchen
country: Germany
facility: Klinikum der Universitaet Muenchen; Campus Großhadern; Medizinische Klinik III und Poliklinik
city: Münster
country: Germany
facility: Westfälische Wilhelms-Universität Münster, Medizinische Klinik und Poliklinik A
city: Oldenburg
country: Germany
facility: Klinikum Oldenburg gGmbH; Klinik für Onkologie und Hämatologie
city: Recklinghausen
country: Germany
facility: Prosper-Hospital, Medizinische Klinik I
city: Siegen
country: Germany
facility: St Marien Krankenhaus; Medizinische Klinik Iii
city: Trier
country: Germany
facility: Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie
city: Trier
country: Germany
facility: Krankenhaus der Barmherzigen Brüder Trier; Innere Medizin I, Hämatologie / Internistische Onkologie
city: Tübingen
country: Germany
facility: Eberhard-Karls-Universität Tübingen; Medizinische Klinik I
city: Ulm
country: Germany
facility: Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.
city: Wiesbaden
country: Germany
facility: HSK Dr.-Horst-Schmidt-Kliniken; Innere Medizin I Kardiologie; Angiologie und Intensivmedizin
city: Wuppertal
country: Germany
facility: Helios Klinik Wuppertal; Medizinische Klinik I
city: Wuppertal
country: Germany
facility: Kliniken St. Antonius; Zentrum Für Innere Medizin, Haematologie/Onkologie
city: Thessaloniki
country: Greece
facility: Georgios Papanikolaou Hospital; Hematology Department
city: Hong Kong
country: Hong Kong
facility: Queen Elizabeth Hospital; Clinical Oncology
city: Hong Kong
country: Hong Kong
facility: Queen Mary Hospital; Dept of Medicine
city: Budapest
country: Hungary
facility: Fov. Onk. Egyesitett Szent Istvan es Szent Laszlo Korhaz; Dept Of Bone Marrow Transplant
city: Budapest
country: Hungary
facility: National Institute of Oncology, A Dept of Internal Medicine
city: Debrecen
country: Hungary
facility: University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology
city: Bologna
country: Italy
facility: A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
state: Emilia-Romagna
city: Parma
country: Italy
facility: Ospedale Regionale Di Parma; Divisione Di Oncologia Medica
state: Emilia-Romagna
city: Reggio Emilia
country: Italy
facility: Az. Osp. Arcispedale S. Maria Nuova; U.O. Di Ematologia
state: Emilia-Romagna
city: Aviano
country: Italy
facility: Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
state: Friuli-Venezia Giulia
city: Udine
country: Italy
facility: A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica
state: Friuli-Venezia Giulia
city: Roma
country: Italy
facility: Univ. Cattolica La Sapienza; Cattedra Di Ematologia
state: Lazio
city: Monza
country: Italy
facility: ASST DI MONZA; Ematologia
state: Lombardia
city: Pavia
country: Italy
facility: Irccs Policlinico San Matteo; Divisione Di Ematologia
state: Lombardia
city: Ascoli Piceno
country: Italy
facility: Ospedale Gen.Le Prov.Le 'C.G.Mazzoni'; Ematologia
state: Marche
city: Campobasso
country: Italy
facility: Università Cattolica Del Sacro Cuore S.S. Giovanni Paolo Ii; Uoc Di Onco-Ematologia
state: Molise
city: Orbassano
country: Italy
facility: Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico
state: Piemonte
city: Torino
country: Italy
facility: A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1
state: Piemonte
city: Bari
country: Italy
facility: Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
state: Puglia
city: Via S. Sofia 78
country: Italy
facility: Ospedale Ferrarotto; Divisione Di Ematologia
state: Sicilia
city: Pisa
country: Italy
facility: Ospedale Santa Chiara; Unita Operativa Di Ematologia
state: Toscana
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Centre; Oncology
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology
city: Seoul
country: Korea, Republic of
facility: Korean Cancer Center Hospital; Oncology
city: Seoul
country: Korea, Republic of
facility: Severance Hospital - Yonsei University; Medicine Dept.
city: Klaipeda
country: Lithuania
facility: Seamen' Hospital' Dept. of haematology
city: Vilnius
country: Lithuania
facility: Uni Hospital Santariskiu Clinic; Haematology
city: Penang
country: Malaysia
facility: Hospital Pulau Pinang
city: Aguascalientes
country: Mexico
facility: Instituto Biomedico De Investigacion A.C.
city: Mexico City
country: Mexico
facility: Hospital Español; Hematología Sala 19
city: Monterrey
country: Mexico
facility: Col Instituto Tecnologico Y Estudios Superiores de Monterrey
city: Monterrey
country: Mexico
facility: Hospital Universitario Dr. Jose E. Gonzalez; Haematology
city: Auckland
country: New Zealand
facility: North Shore Hospital; Haematolgy
city: Auckland
country: New Zealand
facility: Uni of Auckland; Dept of Molecular Medicine & Haematology
city: Christchurch
country: New Zealand
facility: Christchurch Hospital; Canterbury Health Laboratories
city: Panama City
country: Panama
facility: Centro Hemato Oncologico Paitilla
city: Chiclayo
country: Peru
facility: Hospital Nacional Almanzor Aguinaga Asenjo; Unidad De Investigacion Del Servicio De Oncologia Medica
city: Lima
country: Peru
facility: Hospital Nacional Edgardo Rebagliati Martins; Oncologia
city: Lima
country: Peru
facility: Hospital Nacional Guillermo Almenara Irigoyen; Oncology
city: Lima
country: Peru
facility: Instituto Nacional de Enfermedades Neoplasicas
city: Lima
country: Peru
facility: Hospital Nacional LNS dela Policia Nacional del Perú. Unidad Onco; Deapartamento de Oncología
city: Cebu
country: Philippines
facility: Cebu Cancer Institute; Perpetual Succour Hospital
city: Diliman, Quezon City
country: Philippines
facility: National Kidney and Transplant Institute; Chemotherapy Unit
city: Quezon City
country: Philippines
facility: St Luke'S Medical Centre; Oncology
city: Brzozów
country: Poland
facility: Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny
city: Krakow
country: Poland
facility: Szpital Uniwersytecki W Krakowie; Klinika Hematologii
city: Lodz
country: Poland
facility: Medical University School; Dept. of Haematology
city: Lublin
country: Poland
facility: Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie
city: Olsztyn
country: Poland
facility: Zaklad Opieki Zdrowotnej Mswia; Oddzial Chemioterapii
city: Warszawa
country: Poland
facility: Samodzielny Publiczny Centralny Szpital Kliniczny; Haematology Dept.
city: Warszawa
country: Poland
facility: Centralny Szpital Kliniczny Mswia; Klinika onkologii, hematologii i chorob wewnetrznych
city: Warszawa
country: Poland
facility: Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Lymphoma Dept.
city: Coimbra
country: Portugal
facility: HUC; Servico de Hematologia
city: Lisboa
country: Portugal
facility: IPO de Lisboa; Servico de Hematologia
city: Porto
country: Portugal
facility: Hospital de Sao Joao; Servico de Hematologia Clinica
city: Kazan
country: Russian Federation
facility: Republican Clinical Oncologic Dispensary of Republic Of Tatarstan
city: Moscow
country: Russian Federation
facility: N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis
city: Moscow
country: Russian Federation
facility: Haematology Research Center; Haematology
city: Moscow
country: Russian Federation
facility: Semashko Central Clinical Hospital Moscow; Hematology
city: St Petersburg
country: Russian Federation
facility: Research Inst. of Hematology & Blood Transfusion ; Hematology
city: Bratislava
country: Slovakia
facility: National Cancer Inst. ; Dept. of Chemotherapy
city: Terrassa
country: Spain
facility: Hospital Mutua de Terrassa; Servicio de Hematologia
state: Barcelona
city: Santander
country: Spain
facility: Hospital Universitario Marques de Valdecilla; Servicio de Hematologia
state: Cantabria
city: La Coruna
country: Spain
facility: Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Hematologia
state: La Coruña
city: La Laguna
country: Spain
facility: Hospital Universitario de Canarias;servicio de Oncologia
state: Tenerife
city: Bilbao
country: Spain
facility: Hospital de Basurto; Servicio de Hematologia
state: Vizcaya
city: Galdakano
country: Spain
facility: Hospital de Galdakano
state: Vizcaya
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron; Servicio de Hematologia
city: Barcelona
country: Spain
facility: Hospital Clínic i Provincial; Servicio de Hematología y Oncología
city: Barcelona
country: Spain
facility: Hospital Duran i Reynals; Servicio de Hematologia
city: Jaen
country: Spain
facility: Complejo Hospitalario de Jaen- Hospital Universitario Medico Quirurgico; Servicio de Hematologia
city: Madrid
country: Spain
facility: Hospital Universitario Clínico San Carlos; Servicio de Hematología
city: Madrid
country: Spain
facility: Hospital Universitario la Paz; Servicio de Hematologia
city: Malaga
country: Spain
facility: Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
city: Salamanca
country: Spain
facility: Hospital Clinico Universitario de Salamanca;Servicio de Hematologia
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocio; Servicio de Hematologia
city: Valencia
country: Spain
facility: Hospital Universitario la Fe; Servicio de Medicina Intena
city: Valencia
country: Spain
facility: Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
city: Zaragoza
country: Spain
facility: Hospital Universitario Miguel Servet; Servicio Hematologia
city: Lund
country: Sweden
facility: Skånes University Hospital, Skånes Department of Onclology
city: Malmö
country: Sweden
facility: Skånes Universitetssjukhus; Kliniska Forskningsenheten Onkologimottagning medicinsk behandling
city: Sundsvall
country: Sweden
facility: Länssjukhuset; Medicinkliniken
city: Uppsala
country: Sweden
facility: Akademiska sjukhuset, Onkologkliniken
city: Zürich
country: Switzerland
facility: Universitätsspital Zürich; Klinik für Onkologie
city: Taipei
country: Taiwan
facility: Veterans General Hospital; Division of Oncology
city: Taipei
country: Taiwan
facility: Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
city: Taoyuan
country: Taiwan
facility: Chang Gung Medical Foundation-Taipei
city: Bangkok
country: Thailand
facility: King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine
city: Bangkok
country: Thailand
facility: National Cancer Inst.
city: Bangkok
country: Thailand
facility: Rajavithi Hospital; Medicine
city: Bangkok
country: Thailand
facility: Siriraj Hospital; Division of Hematology, Department of Medicine
city: Chiang Mai
country: Thailand
facility: Chiang Mai Uni Hospital; Division of Hematology,Dept of Medicine,Faculty of Medicine
city: Khon Kaen
country: Thailand
facility: Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine
city: Birmingham
country: United Kingdom
facility: Birmingham Heartlands Hospital; Department of Haematology
city: Bradford
country: United Kingdom
facility: Bradford Royal Infirmary; Haematology Department
city: Hampshire
country: United Kingdom
facility: North Hampshire Hospital; Dept. of Haematology
city: Harlow
country: United Kingdom
facility: Princess Alexandra Hospital; Department of Haematology
city: Leicester
country: United Kingdom
facility: Leicester Royal Infirmary; Dept. of Medical Oncology
city: Liverpool
country: United Kingdom
facility: Royal Liverpool Uni Hospital; Haematology
city: London
country: United Kingdom
facility: St. George'S Hospital; Haematology
city: Middx
country: United Kingdom
facility: Hillingdon Hospital
city: Oxford
country: United Kingdom
facility: Churchill Hospital; Oxford Cancer and Haematology Centre
city: Sheffield
country: United Kingdom
facility: Royal Hallamshire Hospital; Haematology Dept
city: Sheffield
country: United Kingdom
facility: Weston Park Hospital; Cancer Clinical Trials Centre
city: Wolverhampton
country: United Kingdom
facility: The Royal Wolverhampton Hospitals NHS Trust; Department of Haematology
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
citation: McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, Sehn LH, Venstrom JM. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019 Feb 26;3(4):531-540. doi: 10.1182/bloodadvances.2018020602.
citation: Seymour JF, Pfreundschuh M, Trneny M, Sehn LH, Catalano J, Csinady E, Moore N, Coiffier B; MAIN Study Investigators. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014 Aug;99(8):1343-9. doi: 10.3324/haematol.2013.100818. Epub 2014 Jun 3.